Back to Results
First PageMeta Content
Biology / Neurology / Motor neurone disease / Medicine / Blood–brain barrier / Amyotrophic lateral sclerosis / Creatine / Prize4Life / James Heywood / Rare diseases / Health / ALS Therapy Development Institute


ALS Therapy Development Institute and to-BBB Collaborate on Potential Treatments for Motor Neuron Disease CNS-targeted Liposomal Drug Delivery System Enhances Institute’s Formulation Abilities January 8, 2013 – CAMBR
Add to Reading List

Document Date: 2013-01-08 09:30:54

Open Document

File Size: 562,08 KB

Share Result on Facebook

City

CAMBRIDGE / Taipei / LEIDEN / /

Company

to-BBB Collaborate / Aescap Venture / Industrial Bank of Taiwan Management Corporation / to-BBB Taiwan Ltd. / Biogen Idec / to-BBB / Jonghoud International / Antea Participaties / ALS TDI / /

Country

Taiwan / United States / Netherlands / /

Event

Funding / Business Partnership / /

Facility

ALS Therapy Development Institute / /

IndustryTerm

potential tool / treatment of brain cancer / internal lead product / treatment for the disease / stage biotechnology company focusing / therapeutics for neurodegenerative disorders / /

MedicalCondition

progressive neurodegenerative disease / paralysis / Lou Gehrig’s disease / disease / brain disorders / ALS / aggressive and rapid disease / lateral sclerosis / amyotrophic lateral sclerosis / multiple sclerosis / lysosomal storage diseases / brain cancer / neurodegenerative diseases / neurodegenerative disorders / /

MedicalTreatment

drug delivery system / /

Organization

MDA / RGK Foundation / ALS Therapy Development Institute / Therapy Development Institute / Motor Neuron Disease CNS-targeted Liposomal Drug Delivery System Enhances Institute / /

Person

Steve Perrin / Pieter Gaillard / Lou Gehrig / /

Position

Chief Scientific Officer / CEO / /

Technology

drug delivery / biotechnology / Drug Delivery System / /

URL

www.als.net / /

SocialTag